Exelixis Retains Full Rights From BMS To Develop, Commercialise XL184
XL184, a clinically advanced MET inhibitor, is a collaborative effort of Exelixis and Bristol-Myers Squibb (BMS). Exelixis and BMS entered into development collaboration in December 2008. As per
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.